Clément Morgat1,2,3, Fritz-Line Vélayoudom-Céphise4, Paul Schwartz5, Martine Guyot5, Delphine Gaye6, Delphine Vimont7,8, Jürgen Schulz7,8, Joachim Mazère7,8,5, Marie-Laure Nunes4, Denis Smith9, Elif Hindié7,8,5, Philippe Fernandez7,8,5, Antoine Tabarin4. 1. CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. clement.morgat@chu-bordeaux.fr. 2. University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. clement.morgat@chu-bordeaux.fr. 3. Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. clement.morgat@chu-bordeaux.fr. 4. Department of Endocrinology, USN Haut-Lévêque, 33604, Pessac, France. 5. Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. 6. Department of Radiology, University Hospital of Bordeaux, 33604, Pessac, France. 7. CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. 8. University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. 9. Department of Oncology, University Hospital of Bordeaux, 33000, Bordeaux, France.
Abstract
CONTEXT: Somatostatin receptor scintigraphy with (111)In-pentetreotide (SRS) is used to detect duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). However, SRS has limited sensitivity for this purpose. Positron emission tomography/computed tomography (PET/CT) with (68)Ga-DOTA-TOC has a higher rate of sporadic dpNETs detection than SRS but there is little data for dpNETs detection in MEN1. PURPOSE: To compare the performances of (68)Ga-DOTA-TOC PET/CT, SRS and contrast-enhanced computed tomography (CE-CT) to diagnose dpNETs in MEN1. DESIGN AND SETTING: Single-institution prospective comparative study PATIENTS AND METHODS: Nineteen consecutive MEN1 patients (aged 47 ± 13 years) underwent (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT within 2 months in random order. Blinded readings of images were performed separately by experienced physicians. Unblinded analysis of CE-CT, combined with additional magnetic resonance imaging, endoscopic-ultrasound, (18)F-2-fluoro-deoxy-D-glucose ((18)F-FDG) PET/CT or histopathology results served as reference standard for dpNETs diagnosis. RESULTS: The sensitivity of (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT was 76, 20, and 60 %, respectively (p < 0.0001). All the true-positive lesions detected by SRS were also depicted on (68)Ga-DOTA-TOC PET/CT. (68)Ga-DOTA-TOC PET/CT detected lesions of smaller size than SRS (10.7 ± 7.6 and 15.2 ± 5.9 mm, respectively, p < 0.03). False negatives of (68)Ga-DOTA-TOC PET/CT included small dpNETs (<10 mm) and (18)F-FDG PET/CT positive aggressive dpNETs. No false positives were recorded. In addition, whole-body mapping with (68)Ga-DOTA-TOC PET/CT identified extra-abdominal MEN1-related tumors including one neuroendocrine thymic carcinoma identified by the three imaging procedures, one bronchial carcinoid undetected by CE-CT and three meningiomas undetected by SRS. CONCLUSIONS: Owing to higher diagnostic performance, (68)Ga-DOTA-TOC PET/CT (or alternative (68)Ga-labeled somatostatin analogues) should replace (111)In-pentetreotide in the investigation of MEN1 patients.
CONTEXT: Somatostatin receptor scintigraphy with (111)In-pentetreotide (SRS) is used to detect duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). However, SRS has limited sensitivity for this purpose. Positron emission tomography/computed tomography (PET/CT) with (68)Ga-DOTA-TOC has a higher rate of sporadic dpNETs detection than SRS but there is little data for dpNETs detection in MEN1. PURPOSE: To compare the performances of (68)Ga-DOTA-TOC PET/CT, SRS and contrast-enhanced computed tomography (CE-CT) to diagnose dpNETs in MEN1. DESIGN AND SETTING: Single-institution prospective comparative study PATIENTS AND METHODS: Nineteen consecutive MEN1patients (aged 47 ± 13 years) underwent (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT within 2 months in random order. Blinded readings of images were performed separately by experienced physicians. Unblinded analysis of CE-CT, combined with additional magnetic resonance imaging, endoscopic-ultrasound, (18)F-2-fluoro-deoxy-D-glucose ((18)F-FDG) PET/CT or histopathology results served as reference standard for dpNETs diagnosis. RESULTS: The sensitivity of (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT was 76, 20, and 60 %, respectively (p < 0.0001). All the true-positive lesions detected by SRS were also depicted on (68)Ga-DOTA-TOC PET/CT. (68)Ga-DOTA-TOC PET/CT detected lesions of smaller size than SRS (10.7 ± 7.6 and 15.2 ± 5.9 mm, respectively, p < 0.03). False negatives of (68)Ga-DOTA-TOC PET/CT included small dpNETs (<10 mm) and (18)F-FDG PET/CT positive aggressive dpNETs. No false positives were recorded. In addition, whole-body mapping with (68)Ga-DOTA-TOC PET/CT identified extra-abdominal MEN1-related tumors including one neuroendocrine thymic carcinoma identified by the three imaging procedures, one bronchial carcinoid undetected by CE-CT and three meningiomas undetected by SRS. CONCLUSIONS: Owing to higher diagnostic performance, (68)Ga-DOTA-TOC PET/CT (or alternative (68)Ga-labeled somatostatin analogues) should replace (111)In-pentetreotide in the investigation of MEN1patients.
Authors: Nils F Schreiter; Winfried Brenner; Munenobu Nogami; Ralph Buchert; Alexander Huppertz; Ulrich-Frank Pape; Vikas Prasad; Bernd Hamm; Martin H Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2011-09-17 Impact factor: 9.236
Authors: Samira M Sadowski; Corina Millo; Candice Cottle-Delisle; Roxanne Merkel; Lily A Yang; Peter Herscovitch; Karel Pacak; William F Simonds; Stephen J Marx; Electron Kebebew Journal: J Am Coll Surg Date: 2015-04-20 Impact factor: 6.113
Authors: I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2007-05-23 Impact factor: 9.236
Authors: Max B Albers; Damiano Librizzi; Caroline L Lopez; Jerena Manoharan; Jonas C Apitzsch; Emily P Slater; Carmen Bollmann; Peter H Kann; Detlef K Bartsch Journal: World J Surg Date: 2017-06 Impact factor: 3.352
Authors: Virendra A Patil; Manjunath R Goroshi; Hina Shah; Gaurav Malhotra; Priya Hira; Vijaya Sarathi; Vikram R Lele; Swati Jadhav; Anurag Lila; Tushar R Bandgar; Nalini S Shah Journal: World J Nucl Med Date: 2020-01-29